Government Support For Sentinext As It Raises Vaccine Funds
This article was originally published in PharmAsia News
The private Malaysian biotech firm Sentinext has raised new funds to help progress its lead candidate vaccine into clinical trials.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.